Results 31 to 40 of about 682,778 (301)
BMC Cardiovascular Disorders, 2021 Background The impact of acute total occlusion (TO) of the culprit artery in non-ST-segment elevation myocardial infarction (NSTEMI) is not fully established.
Michał Terlecki +11 more
doaj +1 more source
Chronic Kidney Disease and Arterial Stiffness: A Two-Way Path
Frontiers in Medicine, 2021 The kidney-heart relationship has raised interest for the medical population since its vast and complex interaction significantly impacts health. Chronic kidney disease (CKD) generates vascular structure and function changes, with significant hemodynamic
Felipe Inserra +6 more
doaj +1 more source
Arterial Hypertension and Risk of Mortality in Patients with COVID-19 Infection
Southeastern European Medical Journal, 2022 COVID-19 is currently a major global health concern. Among many unanswered questions related to COVID-19, some of the most debated ones are those concerning arterial hypertension.
Nikolina Bukal +8 more
doaj +1 more source
Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival [PDF]
, 2017 In pulmonary hypertension (PH), right ventricular (RV) performance determines survival. Pulmonary artery (PA) stiffening is an important biomechanical event in PH and also predicts survival based on the PA relative area change (RAC) measured at rest ...
Bellofiore, Alessandro +6 more
core +1 more source
Pulmonary arterial hypertension [PDF]
Orphanet Journal of Rare Diseases, 2013 Abstract Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right heart failure and ultimately death if untreated. The first classification of PH was proposed in 1973. In 2008, the fourth World Symposium on PH held in Dana Point (California, USA) revised previous classifications.
Montani, David +12 more
openaire +3 more sources
Pulmonary Arterial Hypertension
Journal of the American College of Cardiology, 2008 Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes.
Chin, Kelly M., Rubin, Lewis J.
openaire +4 more sources
Irisin and Cardiometabolic Disorders in Obesity: A Systematic Review
International Journal of Inflammation, 2023 Background. Overweight and obesity are global health issues, impacting a significant portion of young adults. Obesity is a complex condition influenced by genetics and environmental factors, leading to increased susceptibility to cardiovascular diseases (
Jorge da Silva Pinho-Jr +6 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim: to study cerebral blood flow and cholesterol metabolism in menopausal women with arterial hypertension (AH); to evaluate dynamics of cerebral blood flow parameters and plasma lipid concentrations in these patients during 6-month antihypertensive and
V. V. Yakusevich +3 more
doaj +1 more source
ERJ Open Research, 2023 Background The 2022 ESC/ERS guidelines on pulmonary hypertension recommend noninvasive risk assessments based on three clinical variables during follow-up in patients with pulmonary arterial hypertension (PAH).
Jonna Ostermann +6 more
doaj +1 more source
Quantification of Pulmonary Arterial Wall Distensibility Using Parameters Extracted from Volumetric Micro-CT Images [PDF]
, 1999 Stiffening, or loss of distensibility, of arterial vessel walls is among the manifestations of a number of vascular diseases including pulmonary arterial hypertension.
Dawson, Christopher A +3 more
core +2 more sources